Impact of time to metastatic disease onset and extent of disease volume across metastatic hormone-sensitive and castration-resistant prostate cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: Urologic oncology: Seminars and original investigations, 42.2024, 11, S. 371.e11-371.e18
- Event
-
Veröffentlichung
- (where)
-
Frankfurt am Main
- (who)
-
Universitätsbibliothek Johann Christian Senckenberg
- (when)
-
2024
- Creator
- DOI
-
10.1016/j.urolonc.2024.06.016
- URN
-
urn:nbn:de:hebis:30:3-866080
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:28 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Wenzel, Mike
- Höh, Robert Benedikt
- Kopf, Philipp
- Siech, Carolin
- Humke, Clara Julia
- Würnschimmel, Christoph
- Steuber, Thomas
- Graefen, Markus
- Preißer, Felix
- Traumann, Miriam
- Banek, Séverine
- Kluth, Luis
- Chun, Felix
- Mandel, Philipp
- Universitätsbibliothek Johann Christian Senckenberg
Time of origin
- 2024
Other Objects (12)
Diagnosis of clinically significant prostate cancer diagnosis without histological proof in the prostate-specific membrane antigen era: the jury is still out
Entstehung von oxidativen Stressmarkern in DNA und RNA nach der Behandlung mit den Hormonen Angiotensin II und Aldosteron in vitro und in vivo : Vergleich von drei Analysemethoden zum Nachweis von 8-Oxo-2'-desoxyguanosin in LLC-PK1-Zellen
Contemporary treatment patterns and oncological outcomes of metastatic hormone-sensitive prostate cancer and first- to sixth- line metastatic castration-resistant prostate cancer patients
Metastatic Squamous Cell Carcinoma of the Urinary Bladder: Urgent Call for New Therapies
Public Education, Accountability, and Yardstick Competition in a Federal System
Editorial Comment to Testicular cancer and YouTube: What do you expect from a social media platform?
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities
Management and treatment options for patients with de novo and recurrent hormone-sensitive oligometastatic prostate cancer
Diagnosis of clinically significant prostate cancer diagnosis without histological proof in the prostate-specific membrane antigen era: the jury is still out
Entstehung von oxidativen Stressmarkern in DNA und RNA nach der Behandlung mit den Hormonen Angiotensin II und Aldosteron in vitro und in vivo : Vergleich von drei Analysemethoden zum Nachweis von 8-Oxo-2'-desoxyguanosin in LLC-PK1-Zellen
Contemporary treatment patterns and oncological outcomes of metastatic hormone-sensitive prostate cancer and first- to sixth- line metastatic castration-resistant prostate cancer patients
Metastatic Squamous Cell Carcinoma of the Urinary Bladder: Urgent Call for New Therapies
Public Education, Accountability, and Yardstick Competition in a Federal System
Editorial Comment to Testicular cancer and YouTube: What do you expect from a social media platform?
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities
Management and treatment options for patients with de novo and recurrent hormone-sensitive oligometastatic prostate cancer
Diagnosis of clinically significant prostate cancer diagnosis without histological proof in the prostate-specific membrane antigen era: the jury is still out
Entstehung von oxidativen Stressmarkern in DNA und RNA nach der Behandlung mit den Hormonen Angiotensin II und Aldosteron in vitro und in vivo : Vergleich von drei Analysemethoden zum Nachweis von 8-Oxo-2'-desoxyguanosin in LLC-PK1-Zellen
Contemporary treatment patterns and oncological outcomes of metastatic hormone-sensitive prostate cancer and first- to sixth- line metastatic castration-resistant prostate cancer patients
Metastatic Squamous Cell Carcinoma of the Urinary Bladder: Urgent Call for New Therapies
Public Education, Accountability, and Yardstick Competition in a Federal System
Editorial Comment to Testicular cancer and YouTube: What do you expect from a social media platform?
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities